Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis
- PMID: 19690648
- PMCID: PMC2716782
Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis
Abstract
We designed the present case-control study in order to examine the validity of apolipoprotein (apo) A-I, B, apoB/apoA-I ratio and Lp(a) as alternative markers of cardiovascular morbidity in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis (HD). Twenty-five HD patients (18 males, mean age 63, range 52-69 years) comprised the group with prevalent cardiovascular disease (CVD) and 50 HD patients (35 males, mean age 62, range 40-77 years) with non evident cardiovascular disease history constituted the second study group. Patients with CVD had significantly higher concentrations of serum apoB, apoB/apoA-I ratio and Lp(a), and lower levels of apoA-I compared to patients without incident CVD. All three parameters studied were correlated with cardiovascular morbidity, i.e. apoA-I negatively and apoB and apoB/apoA-I ratio positively (r = -0.6, P < 0.05; r = 0.659, P < 0.01; and r = 0.614, P < 0.01, respectively). Furthermore, logCRP exhibited as well a significant positive correlation with cardiovascular morbidity (r = 0.704, P < 0.001), not this being the case for Lp(a) which was not found to exhibit such a correlation (r = 0.05, P = NS). Among them, apoB and apoB/apoA-I ratio exhibited the characteristics most coherent to CVD. The age- and sex-adjusted OR for the presence of CVD was 2.3 and 2.0, respectively, which remained independent of any confounding effect of inflammation. In conclusion, serum apoB levels and apoB/apoA-I ratio exhibit characteristics of credible independent markers of in HD patients.
Keywords: apolipoproteins; cardiovascular disease; hemodialysis; lipids; lipoprotein (a); validation.
Similar articles
-
Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.Med Sci Monit. 2006 Feb;12(2):CR55-62. Epub 2006 Jan 26. Med Sci Monit. 2006. PMID: 16449948
-
Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis.PLoS One. 2017 May 18;12(5):e0177980. doi: 10.1371/journal.pone.0177980. eCollection 2017. PLoS One. 2017. PMID: 28542510 Free PMC article.
-
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.Diabetologia. 2010 Sep;53(9):1846-55. doi: 10.1007/s00125-010-1806-9. Epub 2010 Jun 6. Diabetologia. 2010. PMID: 20526762 Clinical Trial.
-
The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.J Intern Med. 2006 May;259(5):493-519. doi: 10.1111/j.1365-2796.2006.01643.x. J Intern Med. 2006. PMID: 16629855 Review.
-
The concept of apolipoprotein-defined lipoprotein families and its clinical significance.Curr Atheroscler Rep. 2003 Nov;5(6):459-67. doi: 10.1007/s11883-003-0036-8. Curr Atheroscler Rep. 2003. PMID: 14525679 Review.
Cited by
-
Association Between Apo Lipoprotein B Levels at Admission of Patients and Short-term Morbidity and Mortality After Myocardial Infarction.J Cardiovasc Thorac Res. 2012;4(3):61-4. doi: 10.5681/jcvtr.2012.015. Epub 2012 Sep 23. J Cardiovasc Thorac Res. 2012. PMID: 24250986 Free PMC article.
-
A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives.Int Urol Nephrol. 2019 Jul;51(7):1173-1189. doi: 10.1007/s11255-019-02170-w. Epub 2019 May 22. Int Urol Nephrol. 2019. PMID: 31119518 Review.
-
Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease.J Diabetes Res. 2019 Dec 14;2019:6906278. doi: 10.1155/2019/6906278. eCollection 2019. J Diabetes Res. 2019. PMID: 31915710 Free PMC article. Review.
-
Effect of L-carnitine supplementation on lipid profile and apolipoproteins in children on hemodialysis: a randomized placebo-controlled clinical trial.Pediatr Nephrol. 2021 Nov;36(11):3741-3747. doi: 10.1007/s00467-021-05080-1. Epub 2021 May 26. Pediatr Nephrol. 2021. PMID: 34037885 Clinical Trial.
References
-
- Abbott RD, Garrison RJ, Wilson PW, et al. Joint distribution of lipoprotein cholesterol classes. The Framingham Study. Arteriosclerosis. 1983;3:260–72. - PubMed
-
- Adult Treatment Panel III. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001;285:2486–97. - PubMed
-
- Chan PC, Persaud J, Varghese Z, Kingstone D, Baillod RA, Moorhead JF. Apolipoprotein B turnover in dialysis patients: its relationship to the pathogenesis of hyperlipidemia. Clin Nephrol. 1989;31:88–95. - PubMed
-
- Chan DC, Watts GF. Apolipoproteins as markers and managers of coronary risk. Q J M. 2006;99:277–87. - PubMed
-
- Coresh J, Longenecker JC, Miller E.R., 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl 12):S24–S30. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous